Additional manufacturing site for SpikevaxĬHMP has also approved an additional manufacturing site for the production of Spikevax, the COVID-19 vaccine developed by Moderna. The site will allow to provide approximately up to 51 million additional doses in 2021.ĮMA has also approved a new manufacturing line at BioNTech’s manufacturing site in Marburg, Germany which increases the active substance manufacturing capacity by approximately 410 million doses in 2021.

The site, located in Saint Rémy sur Avre, France, is operated by Delpharm and will manufacture finished product. Additional manufacturing site and scaled-up process for ComirnatyĬHMP has approved an additional manufacturing site for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.

EMA’s human medicines committee ( CHMP) has adopted recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU.